In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

Journal of Clinical Virology

Volumn 31, Issue 1, 2004, Pages 69-75

  Chen, F ^a   Chan, K H ^a   Jiang, Y ^b   Kao, R Y T ^a   Lu, H T ^a   Fan, K W ^a   Cheng, V C C ^a   Tsui, W H W ^a   Hung, I F N ^a   Lee, T S W ^a   Guan, Y ^a   Peiris, J S M ^a   Yuen, K Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Antiviral compounds; Epidemics; Severe acute respiratory syndrome

Indexed keywords

ABACAVIR; ACICLOVIR; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMANTADINE; ANTIVIRUS AGENT; ARTEMISIA APIACEA EXTRACT; ASTRAGALUS MEMBRANACEUS EXTRACT; BAICALIN; BETA1A INTERFERON; BUPLEURUM CHINENSE EXTRACT; CHLOROGENIC ACID; CIDOFOVIR; EPHEDRA EXTRACT; FLOS LONICERAE EXTRACT; FOSCARNET; GANCICLOVIR; GLYCYRRHIZA URALENSIS EXTRACT; GLYCYRRHIZIC ACID; INTERFERON ALFANATIVE; LOPINAVIR; NEVIRAPINE; PLANT EXTRACT; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIMANTADINE; RITONAVIR; SCUTELLARIA BAICALENSIS EXTRACT; STAVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ADULT; ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BUPLEURUM; CELL LINE; CERCOPITHECIDAE; CHINESE HERB; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FETUS; HUMAN; INOCULATION; MALE; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SARS CORONAVIRUS; SERODIAGNOSIS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS ISOLATION;

ADULT; ANTIVIRAL AGENTS; CELL LINE; CHLOROGENIC ACID; DRUG SYNERGISM; FEMALE; FLAVONOIDS; GLYCYRRHIZIC ACID; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PLAQUE ASSAY; PYRIMIDINONES; RIBAVIRIN; RIMANTADINE; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 3543143713     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.03.003     Document Type: Article

References (24)

1. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 361:2003a;2045-2046
2. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Treatment of SARS with human interferons. Lancet. 362:2003;293-294
3. Chu C.M., Cheng V.C., Hung I.F., Wong M.M., Chan K.H., Chan K.S., et al. The role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 59:2004;252-256
4. Donnelly C.A., Ghani A.C., Leung G.M., Hedley A.J., Fraser C., Riley S., et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet. 361:2003;1761-1766
5. Douglas R.M., Moore B.W., Miles H.B., Davies L.M., Graham N.M., Ryan P., et al. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N. Engl. J. Med. 314:1986;65-70
6. Eron L.J., Toy C., Salsitz B., Scheer R.R., Wood D.L., Nadler P.I. Therapy of genital herpes with topically applied interferon. Antimicrob. Agents Chemother. 31:1987;1137-1139
7. Fan S.X., Skillman D.R., Liao M.J., Testa D., Meltzer M.S. Increased efficacy of human natural interferon alpha (IFN-alpha n3) versus human recombinant IFN-alpha 2 for inhibition of HIV-1 replication in primary human monocytes. AIDS Res. Hum. Retroviruses. 9:1993;1115-1122
8. Foster G.R., Rodrigues O., Ghouze F., Schulte-Frohlinde E., Testa D., Liao M.J., et al. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J Interferon Cytokine Res. 16:1996;1027-1033
9. Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science. 302:2003;276-278
10. Hayden F.G., Gwaltney J.M. Jr. Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. J Infect Dis. 150:1984;174-180
11. Higgins P.G., Phillpotts R.J., Scott G.M., Wallace J., Bernhardt L.L., Tyrrell D.A. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob. Agents Chemother. 24:1983;713-715
12. Higgins P.G., Barrow G.I., Tyrrell D.A., Isaacs D., Gauci C.L. The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers. Antiviral Res. 14:1990;3-10
13. Karim A., Ahmed S., Khan A., Steinberg H., Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am. J. Med. Sci. 322:2001;233-235
14. Kitamura K., Honda M., Yoshizaki H., Yamamoto S., Nakane H., Fukushima M., et al. Baicalin, an inhibitor of HIV-1 production in vitro. Antiviral Res. 37:1998;131-140
15. Lebwohl M., Sacks S., Conant M. Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis. Antiviral Res. 17:1992;235-243
16. Li B.Q., Fu T., Dongyan Y., Mikovits J.A., Ruscetti F.W., Wang J.M. Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res. Commun. 276:2000;534-538
17. Lu H.T., Jiang Y., Chen F. Application of high-speed counter-current chromatography to the preparative separation and purification of baicalin from the Chinese medicinal plant Scutellaria baicalensis. J. Chromatogr. A. 1017:2003;117-123
18. Meyers J.D., McGuffin R.W., Neiman P.E., Singer J.W., Thomas E.D. Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J. Infect. Dis. 141:1980;555-562
19. Ogata K., Koga T., Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest. 106:1994;612-613
20. Peiris J.S., Chu C.M., Cheng V.C., Chan K.S., Hung I.F., Poon L.L., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 361:2003;1767-1772
21. Poon L.L., Chan K.H., Wong O.K., Yam W.C., Yuen K.Y., Guan Y., et al. Early diagnosis of SARS Coronavirus infection by real time RT-PCR. J. Clin. Virol. 28:2003;233-238
22. Price R.N. Artemisinin drugs: novel antimalarial agents. Expert Opin. Invest. Drugs. 9:2000;1815-1827
23. Raanani P., Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta. Haematol. 107:2002;133-144
24. World Health Organization. Summary table of SARS cases by country, 1 November 2002-7 August 2003. Available at: http://www.who.int/csr/sars/country/ table2003_09_23/en/. Accessed 29 October 2003.